IMS Named Sole Distributor for RxEnergy NeverDie Lithium Ion Batteries

IMS Named Sole Distributor for RxEnergy NeverDie Lithium Ion Batteries

<0> Integrated Medical Systems International, Inc.Chris Hallman, 800-783-9251 </0>

IMS, a leader in surgical device and instrument management, has been named sole distributor for RxEnergy’s NeverDie™ Lithium Ion Batteries.

Jack Hower, President of Surgical Devices for IMS, said the NeverDie battery virtually eliminates the frustrations, surgical delays and wasted time previously associated with the use of battery powered surgical handpieces.

“It’s hard to believe that in an age of technological miracles, a surgeon would have to stop and change a battery in the middle of a procedure. This battery helps eliminate those interruptions,” Hower said.

The RxEnergy battery is part of IMS’ popular RENEW program, a complete refurbishment that restores Stryker 5 and 6 sets to the manufacturer’s original specifications. The IMS RENEW program offers 50% savings over buying new ... and with the NeverDie battery, some power handpieces will actually perform better than they did when new.

“This advancement benefits the entire surgical team as well as the patient,” Hower said. “It’s the future of cordless power, and it’s available now.”

IMS provides surgical device and instrument management, as well as clinical consulting, for more than 2,500 healthcare facilities nationwide. With facilities in Alabama, Florida, Maryland, and Arizona, IMS provides instrument and device inventory management; real-time online data and tools to track instruments, tissue and implants; restoration of instruments to manufacturers’ performance standards; and on-location clinical personnel to manage sterile processing and interface with the OR. To learn more, visit .

Photos/Multimedia Gallery Available:

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.